MHRA consults on which medicines should carry anti-counterfeit features

MHRA is consulting on products that should have the necessary ‘safety features’ in accordance with European law: the 'black' (non-prescription medicines that shall bear the safety features) and 'white' (prescription medicines that shall not bear the safety features) list.
Directive 2011/62/EU (‘Falsified Medicines Directive’) introduced obligatory ‘safety features’ to verify the authenticity of medicinal products. All prescription medicines will bear the safety features unless they are listed by the European Commission, all non-prescription medicines will not bear the safety features unless they are listed. MHRA seeks views on products that should be listed (MHRA website, 1 August 2014).
Click here for more information about the consultation.

This item is also included in our monthly overview, the NVC Members-only Update. If you have any questions, please contact us: info@nvc.nl, +31-(0)182-512411.